Mucosal Melanoma: Oral, Vulvar, Vaginal & Penile Locations

Mucosal melanoma is a rare and aggressive form of melanoma that arises from melanocytes located in mucous membranes rather than the skin. Unlike cutaneous melanoma, which is strongly linked to UV exposure, mucosal melanoma has no known environmental risk factors and often presents at a more advanced stage due to its hidden anatomical sites. This comprehensive guide focuses on mucosal melanoma occurring in the oral cavity, vulva, vagina, and penis—sites that together account for the majority of cases. Understanding the unique characteristics, symptoms, and treatment challenges of these subtypes is crucial for early detection and improved outcomes.

This rare cancer accounts for only about 1% of all melanomas but carries a poorer prognosis due to its biological aggressiveness and delayed diagnosis. The natural history of the disease varies by location, with some sites exhibiting distinct genetic alterations and clinical behaviors. Because these melanomas arise in areas not routinely examined, patients often experience a prolonged interval between onset of symptoms and definitive diagnosis. Raising awareness among healthcare providers and the public is essential to shorten this interval and improve survival rates.

Oral Melanoma: Gingival, Palatal, and Other Oral Sites

Oral melanoma, also referred to as oral malignant melanoma, is the most common mucosal melanoma site, accounting for roughly 30–40% of all mucosal melanomas. It most frequently arises on the hard palate or gingiva (gums), with gingival melanoma being a particularly common presentation. The condition is more prevalent in older adults, with a slight male predominance. Unlike cutaneous melanoma, oral melanoma is not associated with sun exposure but may be linked to genetic predispositions or local irritation. Early lesions often appear as a pigmented macule or patch that gradually thickens, ulcerates, or bleeds. However, a significant proportion (up to 20%) are amelanotic, making clinical recognition challenging. Symptoms can include a painless swelling, loosening of teeth, ill-fitting dentures, or bleeding. In advanced cases, invasion of underlying bone or regional lymph nodes occurs. Diagnosis is confirmed by biopsy and immunohistochemistry, with markers such as S-100, HMB-45, and Melan-A being characteristic. Treatment involves wide local excision with clear margins, often requiring maxillectomy or mandibulectomy for gingival involvement. Adjuvant radiotherapy may be used for high-risk features. Unfortunately, oral melanoma has a high rate of local recurrence and distant metastasis, leading to a 5-year survival rate of only 15–20%. Regular dental check-ups and self-examination of the oral cavity can aid in early detection.

Vulvar and Vaginal Melanoma

Melanoma of the female genital tract is rare, accounting for less than 1% of all melanomas, but it represents a significant proportion of melanomas at mucosal sites. Vulvar melanoma is more common than vaginal melanoma, with a peak incidence in postmenopausal women. The labia minora and clitoris are the most common vulvar sites, but lesions can occur anywhere on the vulva. Symptoms include a palpable lump, itching, bleeding, discharge, or pain. Because these symptoms are nonspecific, diagnosis is often delayed. Many patients present with advanced disease, and the 5-year survival rate for vulvar melanoma is around 50% for localized disease but drops significantly with regional or distant spread. Vaginal melanoma is even rarer and tends to be more aggressive, with a median survival of less than 2 years. Common vaginal melanoma symptoms include vaginal bleeding, discharge, or a mass. Clinical evaluation often reveals a darkly pigmented or sometimes nonpigmented lesion. Biopsy is essential for diagnosis. Imaging such as PET-CT or MRI is used for staging. Treatment for both vulvar and vaginal melanoma involves surgical excision with clear margins. Due to the anatomical limitations, achieving wide margins can be difficult, and sentinel lymph node biopsy may be employed for vulvar melanoma. Radiation therapy is used for local control in unresectable cases or when margins are positive. Systemic therapies, including immunotherapy (e.g., checkpoint inhibitors) and targeted therapy (if BRAF mutation present), are options for advanced disease. However, BRAF mutations are less common in mucosal melanoma compared to cutaneous melanoma. The role of chemotherapy is limited. Awareness of vulvar melanoma symptoms and the use of images of vulvar melanoma in medical education can help clinicians recognize atypical presentations. Self-examination with a mirror may empower patients to detect changes, though many lesions are not easily visible.

Penile Melanoma

Penile melanoma is an extremely rare malignancy, accounting for less than 1% of all penile cancers and approximately 2% of mucosal melanomas. It typically occurs on the glans penis, prepuce, or urethral meatus. Median age at diagnosis is 60–70 years. Clinically, penile melanoma presents as a pigmented or erythematous nodule, ulcer, or plaque that may bleed or discharge. Because early lesions are painless, patients often delay seeking medical attention. Diagnosis is made by biopsy, and imaging is used for staging. The prognosis is poor, with a 5-year survival rate of around 20–30%, largely due to late presentation and high risk of inguinal lymph node involvement. Treatment is primarily surgical, ranging from wide local excision to partial or total penectomy, depending on tumor size and location. Sentinel lymph node biopsy is recommended for staging, and adjuvant radiation or systemic therapy may be considered. As with other mucosal melanomas, penile melanoma has a lower incidence of BRAF mutations, limiting targeted therapy options. Immunotherapy with checkpoint inhibitors has shown some efficacy in advanced cases. Early diagnosis is critical, and any pigmented lesion on the penis that changes or persists should be evaluated by a dermatologist or urologist.

Diagnosis and Treatment Overview

The diagnosis of mucosal melanomas at any of these sites requires a high index of suspicion and thorough clinical examination. Imaging studies (CT, MRI, PET-CT) are used to assess local extent and distant spread. Biopsy with histopathological and immunohistochemical analysis is mandatory. Genetic testing for BRAF, c-KIT, and NRAS mutations may guide targeted therapy. Treatment follows a multidisciplinary approach involving surgery, radiation oncology, and medical oncology. Surgical excision with clear margins remains the cornerstone of treatment for localized disease. For regionally advanced disease, sentinel lymph node biopsy or complete lymphadenectomy may be performed. Adjuvant radiation is often used for high-risk features such as positive margins or lymph node involvement. Systemic therapies include immunotherapy with anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-CTLA-4 antibodies (ipilimumab), which have shown activity in mucosal melanoma. Targeted therapy is limited to BRAF-mutant cases, which are less frequent. Chemotherapy is generally reserved for palliative settings. Clinical trials exploring novel agents and combinations are ongoing.

Prognosis and Follow-Up

Mucosal malignant melanoma has a worse prognosis than cutaneous melanoma, with an overall 5-year survival rate of approximately 25%. Survival varies by site: oral melanoma has the poorest outlook, while vulvar melanoma has slightly better outcomes if diagnosed early. The high risk of local recurrence and distant metastasis necessitates long-term follow-up with regular clinical examinations and imaging. Patients should be educated on self-examination and recognition of symptom recurrence. Supportive care and palliative interventions are important for advanced disease. Efforts are underway to improve early detection through public education and to develop more effective therapies tailored to the unique biology of mucosal melanoma.

In conclusion, mucosal melanoma at oral, vulvar, vaginal, and penile sites presents significant diagnostic and therapeutic challenges. A multidisciplinary approach and heightened awareness among clinicians and patients are essential to improve outcomes. By understanding the distinct clinical features—such as gingival malignant melanoma and symptoms of vulvar melanoma—healthcare providers can initiate timely biopsies and appropriate treatment. Ongoing research into the molecular drivers of this disease will hopefully yield more effective strategies for management.